SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
acel12170-sup-0001-FigS1-S7-TableS1-S2.docxWord document2643K

Fig. S1 ACA treatment: Site-specific survival curves for UM-HET3 controls (A,B) and ACA-fed male (C) and female (D) mice.

Fig. S2 ACA, EST and MB treatment: weights for UM-HET3 controls and males (A–C) and females (D–F) at TJL (A,D), UM (B,E), and UT (C,F).

Fig. S3 EST treatment: Survival for UM-HET3 control females pooled across sites (A) and EST-treated females at TJL (B), UM (C), and UT (D).

Fig. S4 NDGA treatment: Interim survival for UM-HET3 controls and NDGA-treated males at TJL (A), UM (B), and UT (C), and UM-HET3 controls and NDGA-treated females at TJL (D), UM (E), and UT (F).

Fig. S5 NDGA levels in plasma of UM-HET3 controls and males treated with high (5000 ppm), middle (2500 ppm), or low dose (9800 ppm) of NDGA in the diet (A), and UM-HET3 controls and females treated with high dose of NDGA (B).

Fig. S6 NDGA treatment: Body weights for UM-HET3 controls and males treated with high, middle, and low dose of NDGA (A), and for UM-HET3 controls and females treated with high dose of NDGA (B).

Fig. S7 MB treatment: Survival curves for UM-HET3 controls and mice fed MB in the diet for males at TJL (A), UM (B), and UT (C), and for females at TJL (D), UM (E), and UT (F).

Table S1 ACA and EST treatment: Inferred causes of death in aging UM-HET3 controls and ACA- and EST-treated males and females

Table S2 Survival in UM-HET3 control and male mice that were treated with ACA, EST, and MB in the diet and that lived at least 600 days

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.